HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors

Trial Details

NCT ID

NCT07296341

Phase

PHASE1 / PHASE2

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

• HRS-4642;Adebrelimab Injection; nab-paclitaxel; gemcitabine
• HRS-4642;nab-paclitaxel; gemcitabine

Locations (sample)

• Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

• Age range of 18-75 years old (inclusive of both ends), gender not limited when signing the informed consent form
• ECOG performance status 0 or 1
• Life expectancy of greater than or equal to 12 weeks.
• Subjects with unresectable local advanced or metastatic pancreatic cancer, and pancreatic duct adenocarcinoma confirmed by histopathology

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.